Contineum Therapeutics, Inc.
CTNM
$12.15
-$0.07-0.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.73% | 27.81% | 31.78% | 104.37% | 128.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.40% | 15.09% | 63.58% | 82.38% | 76.18% |
| Operating Income | -0.40% | -15.09% | -63.58% | -82.38% | -76.18% |
| Income Before Tax | -4.06% | -24.59% | -78.04% | -89.97% | -83.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.06% | -24.59% | -78.04% | -89.97% | -87.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.06% | -24.59% | -78.04% | -89.97% | -87.48% |
| EBIT | -0.40% | -15.09% | -63.58% | -82.38% | -76.18% |
| EBITDA | -0.34% | -15.02% | -63.75% | -82.71% | -76.08% |
| EPS Basic | 13.06% | -14.04% | -60.59% | 82.60% | -10.63% |
| Normalized Basic EPS | 13.05% | -14.03% | -60.56% | 82.60% | 83.34% |
| EPS Diluted | 13.06% | -14.04% | -60.59% | 82.60% | -10.63% |
| Normalized Diluted EPS | 13.05% | -14.03% | -60.56% | 82.60% | 83.34% |
| Average Basic Shares Outstanding | 19.69% | 9.27% | 10.88% | 991.93% | 1,002.58% |
| Average Diluted Shares Outstanding | 19.69% | 9.27% | 10.88% | 991.93% | 1,002.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |